$RGBP The NR2F6 nuclear receptor has been identified as a potentially significant immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6, in an effort to unleash the cancer-killing potential of a patient's own immune system, as well as identifying agonists, which should suppress the immune system in diseases where the immune system is over-activated, such as rheumatoid arthritis and other autoimmune diseases.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.